1 research outputs found
Azalmış ejeksiyon fraksiyonu olan kalp yetersizliği hastalarında anjiyotensin reseptörü neprilysin inhibitörü: Türkiye’den gerçek dünya deneyimi (ARNi-TR)
Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angio tensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.Methods: The ARNi-TR is a multicenter, nonintervention al, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was ini tiated at hospitalization or under outpatient clinic control.Results: N-terminal pro-brain natriuretic peptide (NT-proB NP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parame ters, p<0.001) within 1-year follow-up. In both groups, a de crease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypotension (16.9%) was the most common side effect in patients using ARNi.Conclusion: The ARNi-TR study offers comprehensive re al-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proB NP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study